Orion stock pre-market at EUR 81.10: minus 0.10 percent
Published on 10/06/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Orion stock was at EUR 81.10 in pre-market trading at Lang & Schwarz at 7:39 a.m. CEST on October 6, 2026. That was a minus 0.10 percent change versus the Lang & Schwarz prior close of EUR 81.18 on October 5, 2026.
Pre-market indication
The bid was EUR 80.95 and the ask was EUR 81.25 at the recorded time. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Orion stock.
ODM-216 enters clinical testing
In a press release dated October 5, 2026, GlobeNewswire reported that Orion Corporation had dosed the first patient in the BICIDES Phase 1/2 clinical trial of ODM-216. The study is evaluating the candidate’s safety, pharmacokinetics and preliminary anti-tumor activity in patients with advanced solid tumors.
Orion described ODM-216 as its first biologic candidate and first immuno-oncology treatment to enter clinical testing in humans. The investigational treatment is a bispecific antibody targeting PVRIG and PD-L1.
